EDWARD VICTOR PROCHOWNIK
Medical Practice in Pittsburgh, PA
License number
Pennsylvania MD046934L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Pittsburgh, PA 15208
Personal information
See more information about EDWARD VICTOR PROCHOWNIK at radaris.comName
Address
Phone
326 S Dallas Ave, Pittsburgh, PA 15208
326 Dallas Ave, Pittsburgh, PA 15208
Professional information
Dr. Edward V Prochownik, Pittsburgh PA - MD (Doctor of Medicine)
Specialties:
Pediatric Hematology & Oncology
Address:
Pittsburgh Office
4401 Penn Ave SUITE 2000, Pittsburgh 15224
(412) 692-5325 (Phone), (412) 692-6076 (Fax)
Childrens Hematolgy Onclgy Clin
4401 Penn Ave SUITE 9, Pittsburgh 15224
(412) 692-5055 (Phone)
4401 Penn Ave SUITE 2000, Pittsburgh 15224
(412) 692-5325 (Phone), (412) 692-6076 (Fax)
Childrens Hematolgy Onclgy Clin
4401 Penn Ave SUITE 9, Pittsburgh 15224
(412) 692-5055 (Phone)
Certifications:
Pediatric Oncology & Pediatric Hematology, 2012, Pediatrics, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Pittsburgh Office
4401 Penn Ave SUITE 2000, Pittsburgh 15224
Childrens Hematolgy Onclgy Clin
4401 Penn Ave SUITE 9, Pittsburgh 15224
Magee-Womens Hospital of UPMC
300 Halket St, Pittsburgh 15213
4401 Penn Ave SUITE 2000, Pittsburgh 15224
Childrens Hematolgy Onclgy Clin
4401 Penn Ave SUITE 9, Pittsburgh 15224
Magee-Womens Hospital of UPMC
300 Halket St, Pittsburgh 15213
Education:
Medical School
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1978
Childrens Hospital
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
Graduated: 1978
Childrens Hospital
Edward V Prochownik, Pittsburgh PA
Specialties:
Pediatrician
Address:
4401 Penn Ave, Pittsburgh, PA 15224
3705 5Th Ave, Pittsburgh, PA 15213
3705 5Th Ave, Pittsburgh, PA 15213
Education:
University of Chicago, Pritzker School of Medicine - Doctor of Medicine
University of Chicago - Doctor of Philosophy
Children's Hospital Boston - Fellowship - Hematology and Oncology (Internal Medicine)
Children's Hospital Boston - Residency - Pediatrics
University of Chicago - Doctor of Philosophy
Children's Hospital Boston - Fellowship - Hematology and Oncology (Internal Medicine)
Children's Hospital Boston - Residency - Pediatrics
Board certifications:
American Board of Pediatrics Certification in Pediatrics, American Board of Pediatrics Sub-certificate in Pediatric Hematology/Oncology (Pediatrics)
Edward Prochownik, Pittsburgh PA
Work:
Children's Hospital of Pittsburgh
3705 5Th Ave, Pittsburgh, PA 15213 Childrens Hosp Of Pittsburgh Of Upmc
4401 Penn Ave, Pittsburgh, PA 15224 Children's Hospital of Pittsburgh
1 Childrens Hospital Dr, Pittsburgh, PA 15224
3705 5Th Ave, Pittsburgh, PA 15213 Childrens Hosp Of Pittsburgh Of Upmc
4401 Penn Ave, Pittsburgh, PA 15224 Children's Hospital of Pittsburgh
1 Childrens Hospital Dr, Pittsburgh, PA 15224
Pharmacologic Inhibition Of Myc Function
US Patent:
2004003, Feb 19, 2004
Filed:
Jun 12, 2003
Appl. No.:
10/459769
Inventors:
Edward Prochownik - Pittsburgh PA, US
Christine Giap - Pittsburgh PA, US
John Lazo - Pittsburgh PA, US
Xiaoying Yin - Chapel Hill NC, US
Christine Giap - Pittsburgh PA, US
John Lazo - Pittsburgh PA, US
Xiaoying Yin - Chapel Hill NC, US
International Classification:
A61K031/445, A61K031/427, A61K031/4245, A61K031/137
US Classification:
514/317000, 514/364000, 514/369000, 514/424000, 514/649000
Abstract:
The c-Myc oncoprotein, a helix-loop-helix-leucine zipper (HLH-ZIP) transcription factor, is frequently deregulated in human cancers. All known functions of c-Myc, including those pertaining to transformation, require that it heterodimerize with another HLH-ZIP protein, Max. Using a high throughput yeast-based assay, we identified seven low molecular weight substances that inhibit c-Myc-Max association. Each compound also prevented this interaction in vitro and inhibited the growth of c-Myc-expressing fibroblasts, although not of fibroblasts lacking c-Myc. Finally, short-term exposure of c-Myc over expressing fibroblasts to several of the compounds markedly reduced their in vivo tumorigenicity. These studies suggest that yeast-based assays can be used to identify inhibitors of protein-protein interactions and that these frequently function in mammalian cells. The signature specificities of each of the c-Myc-Max compounds identified here further suggest synergistic in vivo function.
Small Molecule Inhibitors Of Cancer Stem Cells
US Patent:
2010029, Nov 25, 2010
Filed:
May 6, 2010
Appl. No.:
12/775023
Inventors:
Edward V. Prochownik - Pittsburgh PA, US
John S. Lazo - Pittsburgh PA, US
John S. Lazo - Pittsburgh PA, US
International Classification:
A61K 31/52, A61K 31/353, A61P 35/00
US Classification:
5142634, 514456
Abstract:
A method of inhibiting a carcinoma in a subject, comprising administering to the subject at least one therapeutic agent that selectively targets carcinoma stem cells. Illustrative carcinoma stem cell-selective therapeutic agents include CGP74514A, rottlerin, and A-77636.
Cancer Stem Cell Immortalization
US Patent:
2011024, Oct 6, 2011
Filed:
Nov 10, 2010
Appl. No.:
12/927225
Inventors:
Edward A. Prochownik - Pittsburgh PA, US
International Classification:
C12Q 1/68, C12N 5/095, C12N 5/10, C12N 15/85, C12Q 1/18, G01N 33/574
US Classification:
435 613, 435325, 4353201, 435 32, 435 723
Abstract:
The present invention relates to the preparation and use of immortalized cancer stem cells. The immortalized cancer stem cells of the invention may be used in assays to identify anti-cancer compounds as well as molecules critical to carcinogenesis. Further, cancer stem cells may be harvested from a patient and used, according to the invention, to select agents more likely to be effective in treating the cancer of that particular patient.
Low Molecular Weight Myc-Max Inhibitors
US Patent:
7872027, Jan 18, 2011
Filed:
Feb 16, 2007
Appl. No.:
11/707421
Inventors:
Steven J. Metallo - Silver Springs MD, US
Edward V. Prochownik - Pittsburgh PA, US
Edward V. Prochownik - Pittsburgh PA, US
Assignee:
University of Pittsburgh - Of the Commonwealth System of Higher Education - Pittsburgh PA
Georgetown University - Washington DC
Georgetown University - Washington DC
International Classification:
A61K 31/427, A61K 31/445, C07D 277/08, C07D 417/02
US Classification:
514326, 546184, 546192, 546209, 548146, 548182, 548183, 514315, 514365, 514369
Abstract:
Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are provided, comprising contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.
Linked Myc-Max Small Molecule Inhibitors
US Patent:
8637556, Jan 28, 2014
Filed:
Jan 15, 2010
Appl. No.:
13/144674
Inventors:
Steven J. Metallo - Silver Spring MD, US
Edward V. Prochownik - Pittsburgh PA, US
Ariele Viacava Follis - Memphis TN, US
Edward V. Prochownik - Pittsburgh PA, US
Ariele Viacava Follis - Memphis TN, US
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education - Pittsburgh PA
Georgetown University - Washington DC
Georgetown University - Washington DC
International Classification:
A61K 31/427, A61K 31/4245, C07D 277/04, C07D 413/02
US Classification:
514364, 514369, 548126, 548183, 435375
Abstract:
Provided herein are compounds and compositions for interfering with the association of Myc and Max. These compounds and compositions are useful in methods for inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell comprise contacting the cell with an amount of a compound that interferes with Myc and Max association effective to inhibit growth or proliferation of the cell.